# US 2026/0273026 A1 · Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0273026 A1
- Document ID: US20260273026A1
- Status: Published application
- Kind: A1
- Application number: 19/633,446
- Filed: 2026-03-30
- Published: 2026-09-17
- Earliest claimed: 2016-08-18
- Assignees: Alkahest, Inc.
- Applicants: Alkahest, Inc.
- Inventors: David Bell; Ian Gallager; Steven P. Braithwaite; S. Sakura Minami; Vu Dang; Joe McCracken; Karoly Nikolich
- Web page: https://patentgrep.com/patent/US20260273026A1

## CPC

- A61K 38/385: {Serum albumin}
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 38/38: Albumins
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

## Claims

### Claim 1

A method of treating a cognitive disorder, comprising administering an effective amount of a Plasma Fraction to a subject diagnosed with a cognitive disorder, wherein the Plasma Fraction is a Human Albumin Solution.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Human Albumin Solution is a commercially available Human Albumin Solution.

### Claim 3 (depends on 1)

The method of claim 1, further comprising monitoring the subject for improved cognitive function.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Plasma Fraction is derived from plasma from a pool of young individuals.

### Claim 5 (depends on 1)

The method of claim 1, wherein the Plasma Fraction is produced from a mammalian blood product.

### Claim 6 (depends on 5)

The method of claim 5, wherein the mammalian blood product is a human blood product.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mammal is a human.
